Preclinical evaluation of tolvaptan and salsalate combination therapy in a Pkd1-mouse model

Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic disorder and an important cause of end stage renal disease (ESRD). Tolvaptan (a V2R antagonist) is the first disease modifier drug for treatment of ADPKD, but also causes severe polyuria. AMPK activators have...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Xuewen, Leonhard, Wouter N., Kanhai, Anish A., Steinberg, Gregory R., Pei, York, Peters, Dorien J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893022/
https://www.ncbi.nlm.nih.gov/pubmed/36743216
http://dx.doi.org/10.3389/fmolb.2023.1058825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893022/
https://www.ncbi.nlm.nih.gov/pubmed/36743216
http://dx.doi.org/10.3389/fmolb.2023.1058825

Ejemplares similares